| Product Code: ETC9958280 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Overview |
3.1 United Kingdom (UK) Country Macro Economic Indicators |
3.2 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume, 2021 & 2031F |
3.3 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market - Industry Life Cycle |
3.4 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market - Porter's Five Forces |
3.5 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.6 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume Share, By Indication, 2021 & 2031F |
4 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing investment in mRNA therapeutics research and development by pharmaceutical companies |
4.2.2 Growing demand for personalized medicine and targeted therapies |
4.2.3 Advancements in mRNA technology leading to more efficient drug development processes |
4.3 Market Restraints |
4.3.1 High costs associated with mRNA therapeutics development and manufacturing |
4.3.2 Regulatory challenges and uncertainties surrounding mRNA-based therapies |
4.3.3 Limited expertise and infrastructure for mRNA therapeutics manufacturing in the UK |
5 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Trends |
6 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market, By Types |
6.1 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market, By Application |
6.1.1 Overview and Analysis |
6.1.2 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume, By Application, 2021- 2031F |
6.1.3 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume, By Viral Vaccines, 2021- 2031F |
6.1.4 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume, By Protein Replacement Therapies, 2021- 2031F |
6.1.5 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume, By Cancer Immunotherapies, 2021- 2031F |
6.2 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume, By Infectious Diseases, 2021- 2031F |
6.2.3 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume, By Metabolic & Genetic Diseases, 2021- 2031F |
6.2.4 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume, By Cardiovascular & Cerebrovascular Diseases, 2021- 2031F |
7 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Import-Export Trade Statistics |
7.1 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Export to Major Countries |
7.2 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Imports from Major Countries |
8 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Key Performance Indicators |
8.1 Number of clinical trials involving mRNA therapeutics conducted in the UK |
8.2 Percentage of pharmaceutical companies outsourcing mRNA therapeutics development and manufacturing to CDMOs in the UK |
8.3 Rate of adoption of mRNA therapeutics in the UK healthcare system |
9 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market - Opportunity Assessment |
9.1 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Opportunity Assessment, By Application, 2021 & 2031F |
9.2 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Opportunity Assessment, By Indication, 2021 & 2031F |
10 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market - Competitive Landscape |
10.1 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenue Share, By Companies, 2024 |
10.2 United Kingdom (UK) mRNA Therapeutics Contract Development & Manufacturing Organization Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here